In this study, we want to learn how clients and therapists brains connect during different situations. Participants in this study will be randomly assigned to receive either supportive counseling, psycho-education, or yoga

This is a research study to find out if giving a combination of drugs (tagraxofusp and azacitidine) will treat your leukemia and keep it inactive for a period of time.

The purpose of this research is to understand how the combination of augmented reality technology and natural language commands can support anyone with programming a robot to perform a task. As robots enter our world, everyday users will need to tell a robot what to do, like an Amazon Alexa or Google Home. With today's robots, this is not possible. That is why we need your help!

We want to learn how personality traits and neuroendocrine systems relate to how people make decisions. We hope this research will contribute to the understanding of decision-making, mental health, and the underlying factors that impact these constructs.

The purpose of this research study is to examine the impact of fat exposure on sugar metabolism in the human brain.

The purpose of this research study is to measure the effect of a genetic variation in the APOE gene and obesity on how sugar enters and is used by the human brain.

The goal of this study is to create a support group and resources for adolescents who identify as both autistic and gender diverse using input from adolescents, parents, and professionals.

This is a research study to learn more about a comination of two drugs (Disitamab Vedotin with Pembrolizumab) compared to chemotherapy in patients with cancer of the urinary tract.

In this study, we want to learn more about a program designed for children diagnosed with Tuberous Sclerosis Complex (TSC) and Emotional Dysregulation (ED). The program involves remote-based, small group interactions with children ages 8-18.

Phase 1a Primary Objective: To determine the recommended dose of LOXO-435 in patients with advanced solid tumors harboring alterations in fibroblast growth factor receptor (FGFR)-3 or its ligands. Phase 1b Primary Objective: To assess the antitumor activity of LOXO-435 as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors harboring prespecified activating FGFR3 alterations.